TY  - BOOK
AU  - Reddy, Uma M
TI  - Antenatal Magnesium and Cerebral Palsy in Preterm Infants
SN  - 1097-6833
PY  - 2015///
KW  - *Cerebral Palsy/bl [Blood]
KW  - *Cerebral Palsy/us [Ultrasonography]
KW  - *Magnesium Sulfate/tu [Therapeutic Use]
KW  - Cerebral Hemorrhage/us [Ultrasonography]
KW  - Cerebral Palsy/pc [Prevention & Control]
KW  - Cerebral Ventricles/us [Ultrasonography]
KW  - Child, Preschool
KW  - Cohort Studies
KW  - Electroencephalography
KW  - Female
KW  - Gestational Age
KW  - Humans
KW  - Infant
KW  - Infant, Newborn
KW  - Infant, Premature
KW  - Leukomalacia, Periventricular/us [Ultrasonography]
KW  - Male
KW  - Maternal Exposure
KW  - Neuroprotective Agents/tu [Therapeutic Use]
KW  - Pregnancy
KW  - MedStar Washington Hospital Center
KW  - Obstetrics and Gynecology, Maternal-Fetal Medicine
KW  - Journal Article
KW  - Randomized Controlled Trial
KW  - Research Support, N.I.H., Extramural
N1  - Available online from MWHC library: 1995 - present
N2  - CONCLUSIONS: MgSO4 given prior to preterm delivery was associated with decreased risk of developing echodensities and echolucencies at <32 weeks gestation. However, this effect can only partially explain the effect of MgSO4 on CP at 2 years of age; OBJECTIVE: To evaluate the relationship of maternal antenatal magnesium sulfate (MgSO4) with neonatal cranial ultrasound abnormalities and cerebral palsy (CP); RESULTS: Intraventricular hemorrhage, periventricular leukomalacia, intracerebral echolucency or echodensity, and ventriculomegaly were all strongly associated with an increased risk of CP. MgSO4 administration did not affect the risk of cranial ultrasound abnormality observed at 35 weeks postmenstrual age or later. However, for the 82% of infants born at <32 weeks gestation, MgSO4 was associated with a reduction in risk of echolucency or echodensity. The reduction in risk for echolucency explained 21% of the effect of MgSO4 on CP (P = .04), and for echodensity explained 20% of the effect (P = .02); STUDY DESIGN: In a randomized trial of MgSO4 or placebo in women at high risk of preterm delivery, up to 3 cranial ultrasounds were obtained in the neonatal period. Images were reviewed by at least 2 pediatric radiologists masked to treatment and other clinical conditions. Diagnoses were predefined for intraventricular hemorrhage, periventricular leukomalacia, intracerebral echolucency or echodensity, and ventriculomegaly. CP was diagnosed at 2 years of age by standardized neurologic examination; TRIAL REGISTRATION: ClinicalTrials.gov: NCT00014989.Copyright Published by Elsevier Inc
UR  - http://dx.doi.org/10.1016/j.jpeds.2015.06.067
ER  -